Informed Consent Form Example Research

HUMAN RESEARCH PARTICIPANT INFORMED CONSENT AND AUTHORIZATION AGREEMENT

DOCUMENT CONTROL & METADATA

• Effective Date: [Effective Date, e.g., November 1, 2023]
• Document Version: [e.g., 2.4]
• Protocol ID / IRB Number: [Institutional Review Board Tracking Number]
• Jurisdiction / Scope: [Applicable State/Federal Jurisdiction, e.g., State of California / United States]

---

1. OFFICIAL NOTICE & LEGAL DISCLAIMER

This document is an advanced legal template designed for institutional and corporate human subjects research. It must be reviewed, modified, and approved by qualified legal counsel and the applicable Institutional Review Board (IRB) or Ethics Committee prior to deployment. This document incorporates baseline standards for the Common Rule (45 CFR 46), the Health Insurance Portability and Accountability Act (HIPAA), and applicable state privacy statutes. Users must ensure all brackets ([...]) are populated with accurate, verified operational data.

---

2. PARTIES & DEFINITIONS

This Informed Consent and Authorization Agreement ("Agreement") is entered into by and between:

• Research Institution / Sponsor: [Full Legal Name of Institution/Company], having its principal place of business at [Physical Address] ("Sponsor" or "Institution"), and
• Participant: [Full Legal Name of Participant], residing at [Participant Address] ("Participant" or "You").

Definitions:

1. "Study" refers to the research protocol entitled [Official Protocol Title], designed to [Briefly state the primary objective of the research].
2. "Data" includes all identifiable and de-identified information collected, derived, or generated from the Participant during the course of the Study, including biological specimens, survey responses, and digital telemetry.
3. "PI" refers to the Principal Investigator, [Name of Principal Investigator], responsible for the execution and oversight of the clinical/operational protocol.

---

3. OPERATIVE CLAUSES & TERMS

SECTION 1: PURPOSE AND NATURE OF THE RESEARCH

1.1 Invitation: You are invited to participate in a research study conducted by [Institution Name]. Participation is entirely voluntary. 1.2 Purpose: The purpose of this Study is to [Detailed scientific or operational objective]. The results of this Study may be published in scientific literature or utilized for commercial product development by the Sponsor.

SECTION 2: PROCEDURES AND TIME COMMITMENT

2.1 Protocol Execution: If you agree to participate, you will be required to complete the following procedures: [List procedures step-by-step: e.g., attend 3 clinical visits, complete bi-weekly online surveys, provide blood samples]. 2.2 Duration: Your participation will span approximately [Number of days/weeks/months], involving [Number] sessions lasting roughly [Number] hours each. 2.3 Location: All physical procedures will take place at [Location/Facility Name], unless otherwise designated as a remote/digital telemetry protocol.

SECTION 3: RISKS, DISCOMFORTS, AND INCONVENIENCES

3.1 Known Risks: Participation in this Study may entail certain risks, including but not limited to: [List specific physiological, psychological, or economic risks, e.g., mild bruising from blood draws, temporary fatigue, potential breach of data confidentiality]. 3.2 Unforeseen Risks: Because the research may involve experimental methodologies, there may be risks that are currently unforeseeable. You will be promptly notified of any significant new findings developed during the course of the Study that may affect your willingness to continue participation.

SECTION 4: BENEFITS

4.1 Direct Benefits: You may not receive any direct medical or professional benefit from participating in this Study. 4.2 General Benefits: Information gathered from this Study may contribute to the scientific understanding of [Field of Study] and assist in the development of future methodologies or products.

SECTION 5: COMPENSATION AND EXPENSES

5.1 Remuneration: Upon successful completion of the Study milestones, you will receive financial compensation in the amount of [Dollar Amount] per [milestone/hour/visit], not to exceed a total of [Total Maximum Dollar Amount]. 5.2 Tax Liability: You acknowledge that you are solely responsible for reporting and paying any applicable local, state, or federal taxes associated with compensation received under this Agreement. 5.3 Injury Compensation: In the event of physical injury resulting directly from research procedures, emergency medical treatment will be made available. [Insert institutional policy regarding financial coverage for research-related injury, e.g., No financial compensation is provided by Sponsor/Institution beyond emergency treatment].

SECTION 6: CONFIDENTIALITY, DATA PROTECTION, AND PRIVACY

6.1 Record Security: All Data collected from you will be stored on secure, encrypted servers compliant with [e.g., HIPAA / GDPR standards] and maintained by [Institution/Sponsor Name]. Access will be restricted to authorized research personnel, the Sponsor, and the reviewing IRB. 6.2 Regulatory Inspection: Representatives of regulatory agencies (such as the U.S. Food and Drug Administration or institutional oversight boards) may review your research records to ensure compliance with applicable standards. 6.3 Publication: Results of this Study may be published in academic or industry forums; however, your identity will remain strictly confidential and will not be disclosed in any publication or report without your explicit written authorization.

SECTION 7: VOLUNTARY PARTICIPATION AND WITHDRAWAL

7.1 Non-Coercion: Your decision to participate is entirely voluntary. Refusing to participate will involve no penalty or loss of benefits to which you are otherwise entitled. 7.2 Right to Withdraw: You reserve the right to withdraw from the Study at any time without penalty or loss of benefits. 7.3 Data Retention Upon Withdrawal: If you withdraw, Data collected prior to your withdrawal may continue to be used and analyzed as part of the research integrity protocol, unless you explicitly request in writing that your identifiable Data be purged, subject to legal and regulatory retention requirements.

SECTION 8: CONTACT INFORMATION

8.1 Questions and Concerns: If you have any questions, concerns, or complaints regarding this Study, or if you sustain a research-related injury, you may contact the Principal Investigator, [PI Name], at [Phone Number] or via email at [Email Address]. 8.2 IRB Inquiries: For questions regarding your rights as a research participant, or to report dissatisfaction with any aspect of the study, you may contact the Institutional Review Board Office at [IRB Phone Number] or [IRB Email Address].

---

4. SIGNATURES & ACKNOWLEDGMENT BLOCK

By signing below, the Participant acknowledges that:

1. They have read and fully understand this Informed Consent and Authorization Agreement.
2. All questions regarding the Study, its procedures, and its risks have been answered to their satisfaction.
3. They voluntarily agree to participate in the research protocol outlined herein.
4. They have received a fully executed copy of this Agreement for their personal records.

PARTICIPANT / SUBJECT

• Full Legal Name: [Participant Full Legal Name]
• Signature: ____________________________________________________
• Date: [MM/DD/YYYY]

INVESTIGATOR / AUTHORIZED REPRESENTATIVE

• I have detailed the nature and demands of the protocol and verified that the Participant understands the contents of this Agreement.
• Printed Name of Pi/Representative: [Investigator Full Legal Name]
• Title: [Professional Title, e.g., Principal Investigator]
• Signature: ____________________________________________________
• Date: [MM/DD/YYYY]

---

5. STEP-BY-STEP EXECUTION GUIDE

1. Customization & Compliance Review: Populate all bracketed fields ([...]) with protocol-specific metrics. Submit the completed document to your designated Institutional Review Board (IRB) or legal compliance officer for formal authorization prior to participant recruitment.
2. Execution & Delivery: Ensure the Participant reads the document in full. Both the Participant and the Principal Investigator (or authorized clinical coordinator) must execute the document via wet-ink signature or a validated, compliant electronic signature platform (e.g., DocuSign, Adobe Sign) ensuring timestamp integrity.
3. Record Archiving: Provide an immediate, fully executed copy of the Agreement to the Participant. Archive the original signed document in a secure, audit-ready regulatory binder or electronic Trial Master File (eTMF) in accordance with institutional data retention policies.